Evidence map›Paper›PMID 40193193›Full record

Trial reportCancer2025

Cladribine, idarubicin, and cytarabine (CLIA) for patients with relapsed and/or refractory acute myeloid leukemia: A single-center, single-arm, phase 2 trial.

Hannah Goulart, Hagop Kantarjian, Gautam Borthakur, Naval Daver, Courtney D DiNardo, Elias Jabbour, Naveen Pemmaraju, Yesid Alvarado, Himachandana Atluri, Musa Yilmaz and 8 more

Registry-linked trialAbstract readClinical Trial, Phase II
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02115295 (Phase II Study of Cladribine Plus Idarubicin Plus Cytarabine), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02115295 phase2recruitingnot on this map

Phase II Study of Cladribine Plus Idarubicin Plus Cytarabine (ARAC) in Patients With AML, HR MDS, or Myeloid Blast Phase of CML

TypeinterventionalSponsorM.D. Anderson Cancer CenterRan2014 to 2030Enrolled508ConditionsAcute Biphenotypic Leukemia, Acute Myeloid Leukemia, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Blasts 10 Percent or More of Bone Marrow Nucleated CellsArmsCladribine, Cytarabine, Gilteritinib, Idarubicin, Laboratory Biomarker Analysis
3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Hannah GoulartDivision of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.ORCID https://orcid.org/0000-0002-1945-2571
Hagop KantarjianDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.ORCID https://orcid.org/0000-0002-1908-3307
Gautam BorthakurDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Naval DaverDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.ORCID https://orcid.org/0000-0001-7103-373X
Courtney D DiNardoDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.ORCID https://orcid.org/0000-0001-9003-0390
Elias JabbourDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.ORCID https://orcid.org/0000-0003-4465-6119
Naveen PemmarajuDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.ORCID https://orcid.org/0000-0002-1670-6513
Yesid AlvaradoDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Himachandana AtluriDivision of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Musa YilmazDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Fadi G HaddadDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.ORCID https://orcid.org/0000-0002-9702-8485
Kayleigh R MarxDivision of Pharmacy, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.ORCID https://orcid.org/0000-0001-9468-9707
Caitlin RauschDivision of Pharmacy, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.ORCID https://orcid.org/0000-0002-4166-5717
Sanam LoghaviDepartment of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Nitin JainDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Guillermo Garcia-ManeroDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.ORCID https://orcid.org/0000-0002-3631-2482
Farhad Ravandi-KashaniDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Tapan M KadiaDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.ORCID https://orcid.org/0000-0002-9892-9832

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Fabien Delerue · 1985 to 2026
$290.8M
NCI NIH HHS P30 CA016672NIH HHS C1100632NIH HHS CA016672Rama Guntupalli Endowment for Leukemia Research
6 · The paper itself

Abstract

backgroundThe treatment of relapsed and/or refractory (R/R) acute myeloid leukemia (AML) remains challenging because of poor responses to chemotherapy. Efforts to improve outcomes have included the use of high-dose cytarabine in combination with nucleoside analogs, such as cladribine. The authors evaluated combined cladribine, idarubicin, and cytarabine (CLIA) in a phase 2 trial of 66 patients with R/R AML.

methodsPatients received induction with cladribine 5 mg/m

resultsThe composite response rate (complete remission [CR] plus complete remission with incomplete hematologic recovery [CRi]) was 33%; salvage 1 (S1) patients (n = 35) had a CR/CRi rate of 49%. After a 61-month median follow-up, the median overall survival (OS) was 7.9 months, with a median relapse-free survival (RFS) of 9.1 months for those in CR/CRi. The median OS for S1 patients was 12 months, with a median RFS of 10.3 months. For those who received CLIA with sorafenib (n = 22), the CR/CRi rate was 41%, median OS was 8.8 months, and median RFS was 3.8 months. Landmark analysis demonstrated superior OS for patients who proceeded to transplantation compared with patients who did not (median OS, 78 vs. 8.8 months, respectively; p < .001). The 4-week and 8-week mortality rates were 6% and 17%, respectively. Most grade >3 adverse events were related to infection and elevated liver function tests.

conclusionsCLIA is effective for patients with R/R AML and offers a safety profile similar to that of other intensive regimens (ClinicalTrials.gov identifier NCT02115295).

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsCytarabineLeukemia, Myeloid, AcuteNeoplasm Recurrence, LocalAdultAgedCladribineFemaleHumansIdarubicinMaleMiddle AgedRemission InductionSorafenibYoung AdultCladribineCytarabineIdarubicinSorafenibacute myeloid leukemia (AML)chemotherapycladribineclinical trial

Identifiers

PMID40193193
PMCPMC12487958

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.